Prestige Consumer Healthcare Inc. PBH
Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. 10-K, Item 1
- Headquarters
- Tarrytown, NY
- Next results
- around Feb 4, 2027
Where each dollar of revenue went, FY2026
Revenue of $1.1B through the costs to a net profit of $190.3M · income statement of the 10-K
PBH among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
11 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed May 14, 2026 against May 9, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +7.7% ($147.7M to $159.1M) vs revenue -4.3% ($1.1B to $1.1B), +12.0 pts apart
-
Receivables -1.2% ($194.3M to $191.9M) vs revenue -4.3% ($1.1B to $1.1B), +3.1 pts apart
9 more checks with nothing to note
-
Cash from operations $257.6M vs net income $190.3M (FY ending Mar 31, 2026)
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Indefinite-Lived Tradename Impairment Assessments - Summer’s Eve and Monistat; Goodwill Impairment Assessment - North American Women’s Health Reporting Unit
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
11 paragraphs in Risk Factors that were not in the 10-K filed May 9, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
Heightened regulatory activity and expectations worldwide, particularly for sterile eye care products, have contributed to ongoing manufacturing disruptions and capacity constraints across the industry. These conditions have impacted, and we expect they will continue to impact for the foreseeable future, the availability of sterile eye…
-
Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
Regulatory authorities, including the Federal Trade Commission, have increasingly focused on the substantiation of marketing and advertising claims and have commenced enforcement actions against companies for failures to adequately substantiate such claims. As a result, we may face increased scrutiny of our marketing practices, and any…
-
Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
We and certain of our suppliers and customers have faced, and likely will continue to face evolving cybersecurity threats, including ransomware, malware, denial-of-service attacks, credential theft, business email compromise, phishing, social engineering (including AI-enabled impersonation), supply chain attacks and other attempts to…
-
Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
The use of artificial intelligence technologies presents operational, legal and regulatory risks.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B |
| Net income | −$82.3M | $209.3M | $214.6M | $190.3M |
| Operating cash flow | $229.7M | $248.9M | $251.5M | $257.6M |
| Free cash flow | $221.9M | $239.4M | $243.3M | $246.4M |
Revenue, FY2017 to FY2026
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.1B ▼ 4.3% in FY2026$190.3M ▼ 11.3% in FY2026$246.4M ▲ 1.3% in FY2026
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 5, 2026Quarterly results, Regulation FD disclosure 8-K items 2.02, 7.01
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Prestige Consumer Healthcare Inc., Tarrytown, NY · from the 10-K filed May 14, 2026
Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., “2026”) refers to our fiscal year ended March 31 of that year.
- Headquarters
- Tarrytown, NY
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- March 31
- Last results
- Nov 5, 2026
Email alerts
Sources
The 10-K filed May 14, 2026 (open at SEC), compared with the 10-K filed May 9, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PBH/export.csv") into a cell.